According to Fierce Pharma (May 11, 2026),
CSL slashes revenue projection and takes $5B impairment as interim CEO flags R&D misses, market erosion. For details, please refer to the original report: https://www.fiercepharma.com/pharma/csl-slashes-revenue-projection-4-and-takes-5b-impairment